OnKure Therapeutics, Inc.
$4.20
+1.9%OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.9).
Valuation inputs: P/E -0.9, earnings yield N/A, momentum +1.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.1%, ROIC -1.1%).
Profitability stack: net margin 0.0%, ROE -1.1%, ROIC -1.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +9.6%, momentum +1.9%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
OnKure Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
OnKure Therapeutics, Inc. Fair Value Envelope
No Revenue Data
OKUR has not reported any revenue values in the available annual periods.
OnKure Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
OKUR has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
OKUR has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
OKUR has not reported any net profit margin values in the available annual periods.
OnKure Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
OnKure Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
OnKure Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that OKUR stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 35.00, with estimates ranging from a low of 35.00 to a high of 35.00.
The consensus 1-year price target stands at 35.00, with estimates ranging from a low of 35.00 to a high of 35.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
OnKure Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $5K worth of OKUR shares, with no buying activity reported.
3 Months
0
0.00
387
1.61K
-2K
-$2K
3-6 Months
0
0.00
389
1.15K
-1K
-$1K
6-9 Months
0
0.00
391
1.02K
-1K
-$1K
9-12 Months
0
0.00
391
931.00
-931
-$931
Top Buyers
No buying activity
Top Sellers
Leverone Jason A.
Officer: Chief Financial Officer
$4K
Saccomano Nicholas A
Director, Officer: President And Ceo
$1K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $5K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
No Dividend Yield Data
OKUR has not reported any dividend yield values in the available annual periods.
okur Dividend History
Learning Layer
Related Guides
Build conviction on OKUR by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.